Whalesbook
Toh bhaiyo, May 19, 2026 ko Zydus Lifesciences ki board meeting hone wali hai, aur sabse bada point hai share buyback ka decision. Company decide kar sakti hai ki woh apne shares market se wapas kharedegi. Is meeting mein FY26 ke Q4 aur poore saal ke audited financial results bhi discuss honge.
Ye announcement aane se pehle, May 13, 2026 ko stock price mein thoda 0.92% ka pump dikha tha, stock ₹939.25 pe band hua. Aur haan, insiders ke liye trading window May 21, 2026 tak close rahegi, jo insider trading rules ke hisaab se hai.
Ab investors ki baat karein toh yahan kuch interesting ho raha hai. Promoter holding toh 75.00% par stable hai. Lekin FIIs (Foreign Investors) ne apni stake thodi kam ki hai, jo pehle 7.06% thi ab 6.95% ho gayi hai. Dusri taraf, DIIs (Domestic Investors) apni holding badha rahe hain, 11.08% se 11.20% kar diya hai. Yahan tak ki Parag Parikh Flexi Cap Fund ne bhi apna stake 1.86% se 1.96% kar liya hai. Ye changes sabko Q4 results aur buyback decision se pehle market ka mood samajhne mein help kar rahe hain.
Valuation ki baat karein toh Zydus ka P/E ratio 18.60 se 19.51 ke beech hai. Ye apne pharma sector ke average P/E ~33.86x ke comparison mein kaafi attractive lag raha hai. Dusre bade players jaise Sun Pharma ka P/E 36.49x se 40.61x hai, jo Zydus se zyada hai. Dr. Reddy's aur Cipla bhi lagbhag Zydus ke aas paas hi hain, 17.5x se 25.58x aur 20.38x se 26.29x ke range mein. Company ka market cap bhi lagbhag ₹93,439.24 Cr se ₹94,948.24 Cr ke aas paas hai. Indian pharma sector overall 11% revenue growth dikha raha hai, lekin costs aur US market pricing ke wajah se thoda pressure hai.
Share buybacks generally achhe maane jaate hain, kyunki isse lagta hai ki management ko lagta hai stock under-valued hai aur EPS badhega. Lekin yahan ek twist hai. Ye buyback Q4 results ke saath ho raha hai. Agar results mein margin pressure ya US market mein slowdown dikha toh investors ko chinta ho sakti hai, kyunki US mein prices kaafi gir rahe hain. Yaad hai, February 2024 mein Zydus ne ₹600 crore ka buyback kiya tha ₹1,005 per share par, jo tab market price se 25% premium tha.
Abhi analysts ne Zydus ko 'Hold' rating di hui hai aur average 12-month target price lagbhag ₹985.41 INR hai. Matlab zyada bada short-term jump shayad na dikhe. Company ka core business toh theek hai, lekin future growth US mein new product launches par depend karegi, jahan pricing kaafi challenging hai. Agar buyback ke liye paisa use kiya gaya toh R&D ya expansion mein der ho sakti hai, jo pharma sector ke liye important hai.
Analysts ko ummeed hai ki Indian pharma sector FY26 mein 7-9% grow karega. Zydus ke liye EPS ₹35.68 se ₹45.19 ke beech expect kiya ja raha hai. Analyst target ek cautious optimism dikha raha hai. Is board meeting ka decision buyback ko lekar bahut important hoga future strategy ke liye.